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Abstract. BACKGROUND: The interferon-free combination of the
protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the
NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnu-
cleoside polymerase inhibitor dasabuvir (also known as ABT-333)
and ribavirin has shown efﬁcacy against the hepatitis C virus
(HCV) in patients with HCV genotype 1 infection. In this phase 3 trial,
we evaluated this regimen in previously untreated patients with HCV
genotype 1 infection and no cirrhosis.
METHODS: In this multicenter, randomized, double-blind, placebo-
controlled trial, we assigned previously untreated patients with
HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consist-
ing of a single-tablet coformulation of ABT-450/r-ombitasvir (at a
once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and
25 mg of ombitasvir), and dasabuvir (250 mg twice daily) with riba-
virin (in doses determined according to body weight) (group A) or
matching placebos (group B). The patients received the study treat-
ment during a 12-week double-blind period. The primary end point
was sustained virologic response at 12 weeks after the end of
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daily; RBV, ribavirin; SVR, sustained virological response.treatment. The primary analysis compared the response rate in
group A with the response rate (78%) in a historical control group
of previously untreated patients without cirrhosis who received
telaprevir with peginterferon and ribavirin. Adverse events occurring
during the double-blind period were compared between group A and
group B.
RESULTS: A total of 631 patients received at least one dose of the
study drugs. The rate of sustained virologic response in group A
was 96.2% (95% conﬁdence interval, 94.5 to 97.9), which was supe-
rior to the historical control rate. Virologic failure during treatment
and relapse after treatment occurred in 0.2% and 1.5%, respectively,
of the patients in group A. The response rates in group A were
95.3% among patients with HCV genotype 1a infection and 98.0%
among those with HCV genotype 1b infection. The rate of discontin-
uation due to adverse events was 0.6% in each study group. Nausea,
pruritus, insomnia, diarrhea, and asthenia occurred in signiﬁcantly
more patients in group A than in group B (P<0.05 for all compari-
sons). Reductions in the hemoglobin level were all of grade 1 or 2;
reductions of grade 1 and 2 occurred in 47.5% and 5.8%, respectively,
of the patients in group A, whereas grade 1 reductions occurred in
2.5% of the patients in group B.
CONCLUSIONS: In previously untreated patients with HCV genotype
1 infection and no cirrhosis, a 12-week multitargeted regimen of
ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effec-
tive and was associated with a low rate of treatment discontinuation.
(Funded by AbbVie; SAPPHIRE-I ClinicalTrials.gov number,
NCT01716585.).
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Patients with HCV cirrhosis are priority candidates for antiviral
treatment, due to the high expected rate of progression to liver
decompensation and eventually to death [1]. Interferon (IFN)-
based dual or triple therapy with 1st generation protease inhibi-
tors is poorly tolerated and has modest efﬁcacy, especially in
patients with marginally compensated or decompensated disease
[2]. CUPIC, a large expanded access French program has shown in
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Fig. 1. Turquoise-II: trial design and results. (A) Trial Design. The Turquoise-II study was an open-label phase 3 trial involving previously untreated and previously treated
adults with HCV genotype 1 infection and compensated cirrhosis. 380 patients with Child-Pugh class A cirrhosis were randomly assigned to receive either 12 or 24 weeks of
treatment with ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and
ribavirin administered according to body weight. (B) Main results: Patients achieved SVR12 of 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms,
respectively (no statistical difference). (C) Results: SVR12 rates by prior treatment response in HCV genotype 1a. Among patients with HCV genotype 1a infection and a prior
null response, 39 of 42 patients in the 24-week group had a SVR12 (92.9% [95% CI, 85.1–100]), as compared with 40 of 50 patients in the 12-week group (80.0% [95% CI,
68.9–91.1]). (D) Results: ITT SVR12 rates by surrogates of portal hypertension and hepatic function.
JOURNAL OF HEPATOLOGYfact that low baseline albumin level (i.e. <35 g/L) combined with
low platelet counts (i.e. <100,000/mm) predict an unfavourable
on-treatment course, with a higher risk of decompensation, infec-
tions and death, together with a low chance of HCV clearance [3].
As the ﬁeld moves rapidly to IFN-free regimen combining
direct-acting antivirals (DAAs), which target multiple viral sites
(NS3/4a protease, NS5B polymerase and NS5A replication com-
plex), sustained virologic response (SVR) rates beyond 90% are
expected in non-cirrhotic patients, regardless of their previous
response to IFN, within 8–12 weeks of therapy and with an excel-
lent tolerability proﬁle [4]. Notwithstanding the major clinical
need of cirrhotics, most IFN-free trials up to now have excluded
patients with cirrhosis or have enrolled only a modest proportion
(10 to 20%) of cirrhotics with well-compensated disease [5–7],
thus negating clinicians the information needed to treat those
patients already bordering on the verge of decompensation.
Our comment deals with a recently published phase III trial
(Turquoise-II) with a paritaprevir (ABT-450) with ritonavir,
ombitasvir, dasabuvir and ribavirin based regimen, performed
exclusively in patients with GT1 HCV cirrhosis ranging from well
to marginally compensated disease [8]. This phase III trial was
performed as a global, multi-centre, randomized, open-labelJournal of Hepatology 2014study including 380 patients with cirrhosis in Child-Pugh class
A5 to A6, randomly assigned to receive either 12 or 24 weeks of
treatment with paritaprevir/r-ombitasvir (at a once-daily dose
of 150 mg of paritaprevir, 100 mg of ritonavir, and 25 mg of
ombitasvir), dasabuvir (250 mg twice daily), and ribavirin
administered according to body weight (Fig. 1A). Cirrhosis was
documented by liver biopsy (Metavir score >3 or Ishak score
>4) or FibroScan result (P14.6 kPa within 6 months before
screening or during screening). Interestingly, key eligibility
criteria were a platelet count of 60,000/mm or more, a serum
albumin level of 2.8 g/dl or more, a total bilirubin level of less
than 3 mg/dl, which makes us think that some patients actually
belonged to Child-Pugh B7 class.
Patients achieved sustained virologic response rates 12 weeks
post-treatment (SVR12) of 91.8% and 95.9% in the 12-week and
24-week treatment arm, respectively (Fig. 1B). Patients in the
study were either treatment naïves or treatment-experienced
(failed previous treatment with pegylated PegIFN and RBV)
(Fig. 1C). A prior null response and infection with HCV subgeno-
type 1a were associated with a lower likelihood of a SVR. Geno-
type 1a and a history of null response were the predictors of
non-SVR in multivariate analysis, and for platelets and albuminvol. 61 j 1430–1433 1431
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there was a non-signiﬁcant trend with indeed an excellent
chance to cure in this population. Interestingly, patients with
low platelets (<109/L) reﬂecting portal hypertension and/or those
with low albumin (<35 g/L), reﬂecting decreased hepatic func-
tion, have a high chance to cure, even though their absolute num-
ber is limited (Fig. 1D). We do not have the precise result in
patients who met these criteria (but the number of patients is
probably limited).
Discontinuation rates due to adverse events were 1.9% (four
patients) and 2.3% (four patients) in the 12-week and 24-week
arm, respectively. The most commonly reported adverse events
(>10 percent in either arm) were fatigue, headache, nausea, pru-
ritus, insomnia, diarrhoea, asthenia, rash, cough, irritability, anae-
mia and dyspnoea. On-treatment virologic failure occurred in one
patient (0.5%) in the 12-week arm and in three patients (1.7%) in
the 24-week arm. In addition, 12 patients (5.9%) in the 12-week
arm and one patient (0.6%) in the 24-week arm experienced
relapse within 12 weeks post-treatment.So, what have we learned from the Turquoise-II study?
First, a regimen with high efﬁcacy in a population previously
deﬁned as ‘‘difﬁcult to cure’’: 12 or 24 weeks of treatment with
co-formulated paritaprevir/r–ombitasvir and dasabuvir, adminis-
tered with ribavirin, resulted in high rates of SVR in patients with
HCV compensated cirrhosis. Notably, approximately 15% of the
study population had platelet counts that were clinically sugges-
tive of portal hypertension. The overall efﬁcacy of the 12-week
and 24-week treatment did not differ signiﬁcantly (91.8% and
95.9%, respectively). Patients with HCV genotype 1a infection
and a null response to prior PegIFN–ribavirin treatment might
beneﬁt from a 24-week treatment duration. In the most severe
patients, again those with low platelets (<109/L) and those with
low albumin, the ideal treatment duration (12 vs. 24 weeks)
remains unknown (SVR = 88% for 12 weeks vs. 97% for 24 weeks).
Second, this is a regimen well-tolerated in this speciﬁc popu-
lation. The majority of adverse events were mild or moderate in
severity, with few events occurring more frequently in the
24-week group than in the 12-week group. Serious adverse
events occurred in 5.5% of all patients, with similar rates in each
group, and few patients discontinued the study treatment
because of adverse events (2.1% overall). A decline in the haemo-
globin level of grade 2 or higher occurred in 7.2% of patients in
the 12-week group and in 11.0% of patients in the 24-week group.
Declines in the haemoglobin level were successfully managed
with modiﬁcations in the ribavirin dose, without a negative effect
on the rate of SVR. Elevations in indirect bilirubin with this reg-
imen are probably related to ribavirin-associated haemolysis,
along with inhibition of the bilirubin transporter OATP1B1 by
ABT-450 (protease inhibitors). Elevated bilirubin levels did not
lead to treatment discontinuation, were not associated with ele-
vations in the alanine aminotransferase level, and resolved to
baseline levels during the post-treatment period.What are the gaps to ﬁll? What should the ideal study
perform?
First, eligibility criteria should be more precisely deﬁned to
include more patients with portal hypertension (oesophageal1432 Journal of Hepatology 2014varices, low platelet count) liver insufﬁciency (low albumin),
Child-Pugh A to B7, and/or compensated cirrhosis who presented
previous decompensation (ascites or bleeding). A better deﬁni-
tion and phenotyping of eligibility criteria should be outlined
since signiﬁcant proportion of patients with an elasticity higher
than 14.8 kPa might have bridging ﬁbrosis (F3) without cirrhosis.
To avoid unexpected issues with salvage therapy, well-designed
studies in Child-Pugh A to B7 and kidney dysfunction should be
performed. In our opinion, patients with concurrent small hep-
ato-cellular carcinoma (HCC) and/or candidates for liver trans-
plantation should be included.
Second, long-term follow-up will be mandatory to demon-
strate cirrhosis reversibility, portal hypertension reduction, HCC
reduction and ﬁnally reduction of liver or not related mortality.
Third, these excellent results, however, should be conﬁrmed
in a large number of patients with predictors of non-response:
in particular in patients with genotype 1b and previous non-
response and with more advanced cirrhosis. In Europe (speciﬁ-
cally southern and eastern Europe) HCV genotype 1b is the most
prevalent one.
Finally, do we need ribavirin in this difﬁcult-to-treat popula-
tion, given the excellent results of this combination and the
adverse events related to ribavirin? We will need to investigate
if ribavirin is necessary.
In conclusion, this large phase III study showed excellent
results in term of efﬁcacy and safety proﬁle in GT1 HCV cirrhotic
patients, in some cases bordering on decompensation. Several
issues are still to be ﬁlled. We will need available IFN-free regi-
men for decompensated cirrhosis and a major issue will be access
to treatment. Phase III data in patients with cirrhosis and other
HCV genotypes, such as genotype 3 and 4, are clearly also an
unfulﬁlled need [9]. While we have to congratulate this impor-
tant addition to our current knowledge, some caution and more
importantly ‘‘real life’’ dataset are still needed, speciﬁcally
regarding safety and drug-drug interactions.Conﬂict of interest
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